Microcap Ledger Kalaris Therapeutics, Inc. $KLRS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Berkeley Heights, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 23,804,981 [10-Q 2026-08-11]
What the company doesAI summary of filing
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing TH103, a novel anti-VEGF fusion protein for retinal diseases. The company is currently conducting a Phase 1b/2 clinical trial of TH103 in patients with neovascular age-related macular degeneration (nAMD), with preliminary Phase 1a data reported in December 2025 showing safety and clinical activity. TH103 is engineered to achieve extended intraocular retention with enhanced VEGF inhibition, potentially allowing for longer intervals between patient treatments compared to existing therapies. The company is pre-revenue and plans to advance TH103 through Phase 3 development and potentially expand into other VEGF-mediated retinal diseases. [10-K 2026-03-17]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$22.37M | −$22.63M | $43.17M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | −$43.43M | −$38.37M | $98.05M | [DEF 14A 2026-04-24] |
| FY ended Dec 2024 | — | −$69.17M | −$20.67M | $1.64M | [DEF 14A 2026-04-24] |
- Quarterly cash burn
- −$11.31M
- Cash runway Estimate
- ~11.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 115,536,550 | [10-Q 2024-11-12] |
| 2025-02-28 | 5,043,357 | [10-K 2025-03-07] |
| 2025-05-07 | 18,702,418 | [10-Q 2025-05-14] |
| 2025-08-06 | 18,702,418 | [10-Q 2025-08-13] |
| 2025-11-05 | 18,702,418 | [10-Q 2025-11-12] |
| 2026-03-10 | 22,928,303 | [10-K 2026-03-17] |
| 2026-05-05 | 23,792,278 | [10-Q 2026-05-12] |
| 2026-08-04 | 23,804,981 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2026-04-03; declared effective 2026-04-13 [S-3 2026-04-03]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-11 | 8-K | Results of operations |
| 2026-07-20 | 8-K | Director or officer change |
| 2026-07-17 | 8-K | Regulation FD disclosure; Other events |
| 2026-07-06 | 8-K | Director or officer change |
| 2026-06-04 | 8-K | Shareholder vote results |
| 2026-05-22 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
| 2026-04-24 | DEF 14A | Proxy statement |
| 2026-04-13 | 424B3 | Prospectus or prospectus supplement |
| 2026-04-13 | 424B3 | Prospectus or prospectus supplement |
Alerts for $KLRS
Email me when Kalaris Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.